QTTB
Q32 Bio Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.99
−6.33%Aug 5, 2026, 10:59 UTC
Q32 Bio Inc. reported its financial results for the second quarter of 2026, with cash and cash equivalents of $106.3 million as of June 30, 2026.
Source:Jul 13, 2026, 20:01 UTC
Q32 Bio Inc. announced an underwritten public offering of $200 million of its common stock and pre-funded warrants.
Jul 13, 2026, 10:59 UTC
Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata, supporting further development and a planned registration-directed program in the first half of 2027.
Jun 29, 2026, 05:57 UTC
Q32 Bio Inc. was added to the Russell Microcap Index.
Source: